Carbenoxolone does not cause a syndrome of mineralocorticoid excess in sheep

Abstract

These studies investigated whether treatment with carbenoxolone (CBX), an inhibitor of 11β-hydroxysteroid dehydrogenase (11β-HSD), resulted in an enhanced mineralocorticoid response to endogenous or infused cortisol. In conscious sodium replete sheep with a parotid fistula, infusion of CBX (40 mg/h for 10 days) did not increase mean arterial pressure, or change sodium and potassium status or plasma renin concentration, but significantly increased the half-life of 1,2[3H] cortisol from 18.6 ± 4.0 to 38.8 ± 3.9 min (p < 0.05) and reduced the blood clearance rate of cortisol (BCR) from 31 ± 3 to 15 ± 4 L/h (p < 0.01). The reduction in cortisol BCR was associated with reduction in cortisol secre..